Consensus Castle Biosciences, Inc.

Stocks

CSTL

US14843C1053

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 00:00:00 27/08/2026 +04			5-day change	1st Jan Change
34.08 ^USD	-2.63%		+5.45%	-12.39%

08-17	Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas	MT
07-31	Castle Biosciences, Inc., Q2 2026 Earnings Call, Jul 30, 2026

Evolution of the Average Target: Castle Biosciences, Inc.

Evolution of the Target Price: Castle Biosciences, Inc.

Changes in Analyst Recommendations: Castle Biosciences, Inc.

ca606bae5d27e39.bjBC4YWoySquK-yaIutLxVBsrftZxeUTdyR9kRPKpy0.CAUvjN36pG7ERqXAbYMyqQkWyJ9r9bBhAhMI1kqv7086eHCt6JCCesFKrQ~fc67c1506669a9b819afdc2017c18ceb

Analysts' recommendations: Castle Biosciences, Inc.

06-25	Roth Capital Initiates Castle Biosciences at Buy	MT
14/12/23	Guggenheim Initiates Castle Biosciences With Buy Rating, $25 Price Target	MT
04/08/23	KeyBanc Adjusts Price Target on Castle Biosciences to $25 From $37, Maintains Overweight Rating	MT
15/06/23	BTIG Research Adjusts Castle Biosciences Price Target to $30 From $38, Maintains Buy Rating	MT
06/06/23	Scotiabank Adjusts Castle Biosciences Price Target to $33 From $54, Maintains Sector Outperform Rating	MT
06/06/23	Canaccord Genuity Adjusts Price Target on Castle Biosciences to $40 From $60, Keeps Buy Rating	MT
05/06/23	SVB Securities Adjusts Price Target on Castle Biosciences to $35 From $50, Maintains Outperform Rating	MT
05/06/23	Lake Street Adjusts Castle Biosciences' Price Target to $32 From $41, Keeps Buy Rating	MT
05/06/23	Baird Adjusts Castle Biosciences Price Target to $25 From $35, Maintains Outperform Rating	MT
05/05/23	KeyBanc Adjusts Price Target on Castle Biosciences to $37 From $40, Maintains Overweight Rating	MT
04/05/23	Baird Adjusts Price Target on Castle Biosciences to $35 From $38, Maintains Outperform Rating	MT
01/03/23	Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating	MT
05/01/23	Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target	MT
03/11/22	Baird Adjusts Castle Biosciences' Price Target to $41 From $48, Keeps Outperform Rating	MT
09/08/22	SVB Securities Adjusts Castle Biosciences' Price Target to $50 from $45, Keeps Market Outperform Rating	MT
09/08/22	Baird Adjusts Castle Biosciences' Price Target to $48 From $44, Maintains Outperform Rating	MT
11/05/22	KeyBanc Adjusts Castle Biosciences' Price Target to $40 from $90, Keeps Overweight Rating	MT
10/05/22	SVB Securities Adjusts Castle Biosciences' Price Target to $45 from $65, Keeps Outperform Rating	MT
10/05/22	Baird Adjusts Price Target on Castle Biosciences to $44 From $50, Keeps Outperform Rating	MT
05/04/22	Canaccord Genuity Adjusts Castle Biosciences Price Target to $80 From $94, Maintains Buy Rating	MT
08/01/22	Stephens Initiates Castle Biosciences With Overweight Rating, $59 Price Target	MT
07/01/22	Stephens Starts Castle Biosciences at Overweight With $59 Price Target	MT
09/11/21	SVB Leerink Adjusts Price Target on Castle Biosciences to $75 From $85, Maintains Outperform Rating	MT
09/11/21	Baird Adjusts Price Target on Castle Biosciences to $82 From $78, Keeps Outperform Rating	MT
10/08/21	Castle Biosciences : Baird Adjusts Castle Biosciences PT to $78 From $73, Maintains Outperform Rating	MT

More recommendations

Diagnostic & Testing Substances

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CASTLE BIOSCIENCES, INC.					+29.11%
	GUARDANT HEALTH, INC.					+13.67%
	BIOMÉRIEUX					+6.38%
	10X GENOMICS, INC.					-22.91%
	CARIS LIFE SCIENCES, INC.					+0.67%
	LANTHEUS HOLDINGS, INC.					+6.17%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+28.16%
	DIASORIN S.P.A.					-5.28%
	AUTOBIO DIAGNOSTICS CO., LTD.					+16.33%
	Average					+8.03%
	Weighted average by Cap.					+6.52%